510(k) Report

510(k) · Cleared

Cleared

Profile-V Medtoxscan Drugs of Abuse Test System and 12 Drugs Test System

K100023510(k) TraditionalCleared Apr 5, 201090-day reviewClass II21 CFR 862.3650

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Medtox Diagnostics, Inc. · DJG Enzyme Immunoassay, Opiates

Cleared on Apr 5, 2010 as substantially equivalent to K091454 (Medtox Diagnostics, Inc., 2009) after a 90-day review. Its family tree reaches back 4 generations to 2002.

Decided
Apr 5, 2010
Review
90 days
Class
Class II
Product code
DJG
Recalls
None
Predicates
1

Its longest line of descent runs back 4 generations to K014101 (2002). 8 ancestors in all, the oldest K973547 (1998). No later device cites it as a predicate yet.

  1. Root · 4 generations backK014101 Rapidone-Oxy TestAmerican Bio Medica Corp. · 2002
  2. 3 generations backK040411 Dri Oxycodone AssayMicrogenics Corp. · 2004
  3. 2 generations backK060351 Medtox OxycodoneMedtox Diagnostics, Inc. · 2006
  4. 1 generation backK091454 Profile-V Medtoxscan Drugs of Abuse Test SystemMedtox Diagnostics, Inc. · 2009
  5. This deviceK100023 Profile-V Medtoxscan Drugs of Abuse Test System and 12 Drugs Test…Medtox Diagnostics, Inc. · 2010
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−4K014101Rapidone-Oxy TestAmerican Bio Medica Corp.2002—
−3K040411Dri Oxycodone AssayMicrogenics Corp.2004—
−2K060351Medtox OxycodoneMedtox Diagnostics, Inc.2006—
−1K091454Profile-V Medtoxscan Drugs of Abuse Test SystemMedtox Diagnostics, Inc.2009—
0 (this device)K100023Profile-V Medtoxscan Drugs of Abuse Test System and 12 Drugs Test SystemMedtox Diagnostics, Inc.2010—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199810
200110
200210
200910
FIG. 1 — Lineage of K100023, 2002–2010Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DJG? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new DJG device

  1. #1 K232659 Dochek® Multi-Drug Urine Test Cup Rx, Dochek®…score 17.6 · 8 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K091454Profile-V Medtoxscan Drugs of Abuse Test System
Summary page 2
…DJ 862.3910, Tricyclic Anti-depressant Drugs Test System LFG Predicate Device: PROFILE®-V MEDTOX Scan®DDrugs of Abuse Test System (K091454) Description of the Device The PROFILE®-V MEDTOXScan®& Drugs of Abuse Test System consists of the PROFILE®-V MEDTOXS…
Medtox Diagnostics, Inc.2009—
†K992111Verdict -II Opiates 2000Medtox Diagnostics, Inc.1999—

Also cleared against K091454: 2 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 8 years and passes through 3 companies; a new generation was cleared every 2.2 years on median.
  • 1 of the 8 ancestors has a recall of any class.
  • 2 other devices also cite its predicate K091454.

How does its category compare?

All DJG devices

DJG Enzyme Immunoassay, Opiates: FDA decisions, review times, recalls and adverse event reports over 20 years. 2010, this device’s year, is highlighted.

FDA decisions per year · DJG

3in 2025

2007: 22008: 22009: 22010: 62011: 62012: 52013: 52014: 92015: 122016: 22017: 42018: 52019: 32020: 52021: 32022: 22023: 102024: 52025: 32026 (partial year): 3
2007high 12 (2015) · low 2 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DJG

31in 2025

2010: 187 days median2011: 233 days median2012: 95 days median2013: 60 days median2014: 62 days median2015: 141 days median2017: 101 days median2018: 134 days median2019: 235 days median2020: 30 days median2021: 422 days median2023: 140 days median2024: 150 days median2025: 31 days median2026 (partial year): 157 days median
2007high 422 (2021) · low 30 (2020)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · DJG

2in 2025

2011: 12019: 12025: 2
2007high 2 (2025) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DJG

1in 2025

2011: 42012: 12013: 42015: 32016: 22017: 12018: 12021: 22022: 12024: 32025: 1
2007high 4 (2011) · low 0 (2007)2025

MAUDE reports naming product code DJG, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20082—00
20092—00
2010618700
2011623314
201259501
201356004
201496200
20151214103
20162—02
2017410101
2018513401
2019323510
202053000
2021342202
20222—01
20231014000
2024515003
202533121
202631570—

What is it indicated for?

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System consists of the PROFILE®-V MEDTOXScan® Test Devices and the MEDTOXScan® Reader. The PROFILE®-V MEDTOXScan® Test Devices are one-step immunochromatographic tests for the rapid, qualitative detection of one or more of the following in human urine: Amphetamines, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Methadone, Methamphetamine, Opiates, Oxycodone, Phencyclidine, Propoxyphene, THC…

Read the full statement (406 words)

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System consists of the PROFILE®-V MEDTOXScan® Test Devices and the MEDTOXScan® Reader. The PROFILE®-V MEDTOXScan® Test Devices are one-step immunochromatographic tests for the rapid, qualitative detection of one or more of the following in human urine: Amphetamines, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Methadone, Methamphetamine, Opiates, Oxycodone, Phencyclidine, Propoxyphene, THC (Cannabinoids), and Tricyclic Antidepressants or their metabolites. The PROFILE®-V MEDTOXScan® Test Devices can only be used with the MEDTOXScan® Reader. The MEDTOX Scan® Reader is an instrument used to interpret and report the results of the PROFILE®-V MEDTOXScan® Test Device. PROFILE®-V MEDTOXScan® Test Devices cannot be visually read.

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System is for in vitro diagnostic use and is intended for professional use only. It is not intended for use in point-of-care settings.

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System detects drug classes at the following cutoff concentrations:

AMP Amphetamine (d-Amphetamine) 500 ng/mL; BAR Barbiturates (Butalbital) 200 ng/mL; BUP Buprenorphine (Buprenorphine) 10 ng/mL; BZO Benzodiazepines (Nordiazepam) 150 ng/mL; COC Cocaine (Benzoylecgonine) 150 ng/mL; MAMP Methamphetamine (d-Methamphetamine) 500 ng/mL; MTD Methadone (Methadone) 200 ng/mL; OPI Opiates (Morphine) 100 ng/mL or 2000 ng/mL; OXY Oxycodone (Oxycodone) 100 ng/mL; PCP Phencyclidine (Phencyclidine) 25 ng/mL; PPX Propoxyphene (Norpropoxyphene) 300 ng/mL; THC (Cannabinoids) (11-nor-9-carboxy-Δ9-THC) 50 ng/mL; TCA Tricyclic Antidepressants (Desipramine) 300 ng/mL.

Configurations of the PROFILE®-V MEDTOXScan® Test Devices may consist of any combination of the above listed and previously cleared drug. Test Devices will have an opiate cutoff of either 100 ng/mL or 2000 ng/mL. Refer to specific product labeling for the combination of drug tests included on that test device.

The PROFILE®-V MEDTOXScan® DRUGS OF ABUSE TEST SYSTEM PROVIDES ONLY A PRELIMINARY ANALYTICAL TEST RESULT. A MORE SPECIFIC ALTERNATE CHEMICAL METHOD MUST BE USED IN ORDER TO OBTAIN A CONFIRMED ANALYTICAL RESULT. GAS CHROMATOGRAPHY / MASS SPECTROMETRY (GC/MS), HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) OR LIQUID CHROMATOGRAPHY / TANDEM MASS SPECTROMETRY (LC/MS/MS) ARE THE PREFERRED CONFIRMATORY METHODS. CLINICAL CONSIDERATION AND PROFESSIONAL JUDGMENT SHOULD BE APPLIED TO ANY DRUG OF ABUSE TEST RESULT, PARTICULARLY WHEN PRELIMINARY POSITIVE RESULTS ARE OBTAINED.

The MEDTOXScan® Reader includes a Positive QC Test Device, a Negative QC Test Device and a Cleaning Cassette. The MEDTOXScan® Positive and Negative QC Test Devices are intended to detect errors associated with the MEDTOXScan® Reader and a contaminated contact imaging sensor (CIS), and to verify that the CIS cleaning procedure using the MEDTOXScan® Cleaning Cassette effectively removed any contamination.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K100023: Profile-V Medtoxscan Drugs of Abuse Test System and 12 Drugs Test System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K100023

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026